Aims: Fingolimod is a sphingosine-1-phosphate (S1P) receptor modulator approved for the treatment of the relapsing form of multiple sclerosis (MS). It prevents the egress of lymphocyte subpopulations from lymphoid tissues into the circulation. Here, we explored the broad effects of fingolimod on gene expression in different immune cell subsets. 
| INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disease of the central nervous system (CNS), which is driven by autoreactive immune cells.
1,2 Distinct B cell and T cell subpopulations play different roles in the initiation and progression of this clinically heterogeneous disease. Activated cytotoxic T cells provoke inflammation and neurodegeneration in the CNS by targeting autoantigenic structures. 3 T helper cells and memory B cells are mediating the destructive processes by presenting antigens and secreting proinflammatory cytokines to costimulate immune responses. 4 The intrathecal formation of antibody-producing plasma cells and plasmablasts is another hallmark of the pathophysiology of MS. 5 Fingolimod is an oral drug approved for the treatment of relapsing-remitting MS (RRMS). 6 As a sphingosine-1-phosphate (S1P) receptor modulator, it affects the migration of lymphocytes out of secondary lymphatic tissues. B cells (from 11% to 6%) and a moderate decrease of CD8+ T cells (from 20% to 15%), 9 while frequencies of CD14+ monocytes and CD56+ natural killer (NK) cells are relatively increased. 10, 11 However, although the altered trafficking of cell subsets has been well studied, the effects of fingolimod on gene expression and cellular signaling are still not fully established.
We examined the transcriptome of lymphocytes and monocytes before and during S1P receptor modulator therapy to obtain further insights on the effects on molecular signatures thought to be related to the pathophysiology of MS. To identify differentially expressed genes (DEG) in immune cells separated from the blood of treated RRMS patients, we measured all human protein-coding and noncoding transcripts at the exon level. The data allowed to analyze to which extent transcriptome changes correlate with the fingolimod-induced shift of circulating cell populations, to investigate gene regulatory programs potentially caused by downstream S1P signaling, and to define molecular markers for monitoring therapeutic responses.
| METHODS
Details about study design and analysis methods were published previously. 12, 13 Briefly, a large dataset comprising 150 high-resolution microarrays was obtained for specific cell populations from blood samples of MS patients. The patients were aged between 26 and 46
and diagnosed with RRMS according to the revised McDonald criteria. 14 Disease duration was, on average, 8 years. All patients were previously treated with either glatiramer acetate or interferon-beta, and none of them received a S1P receptor modulator before. In the 12 months prior to the study, each patient experienced 1-3 relapses.
For this reason, the therapy was switched to fingolimod (standard dose of 0.5 mg orally once daily), following the treatment guidelines and recommendations for routine medical care of the German Society of Neurology. As part of our research on MS, the study was approved by the local ethics committee of the University of Rostock and conducted in accordance with the ethical principles of the Declaration of Helsinki. All patients gave prior written informed consent to participate in this study.
Blood samples (~20 mL) were always taken immediately before the start of fingolimod therapy (baseline) as well as after 24 hours (before the second dose of fingolimod) and after 3 months. Five different cell subsets were magnetically labeled based on the cell surface markers CD4, CD8, CD14, CD19, and CD56 using Whole Blood
MicroBeads from Miltenyi Biotec (Bergisch Gladbach, Germany).
Afterward, the positively selected cell fractions were collected and then counted under a conventional microscope. Total RNA was isolated from the cells using the mirVana Isolation Kit (Thermo Fisher Scientific, Waltham, MA, USA). For each cell population, samples of ten MS patients were prepared to analyze the gene expression in the course of therapy. In doing so, the 3 longitudinal samples for each patient and cell subset were handled at the same day by the same laboratory technician. In total, 150 high-coverage human transcriptome arrays (HTA) 2.0 from Affymetrix (Santa Clara, CA, USA)
were prepared according to the manufacturer's instructions. HTA 2.0 microarrays contain over 6 million 25mer oligonucleotide probes for measuring the transcripts of all coding and noncoding genes.
They are designed with 10 probes per exon fragment and 4 probes per exon-exon splice junction. 15 The probes were summarized in angle regression (TILAR) was employed as described elsewhere.
18,19
We used transcription start sites from the GeneCards database ver- 
| RESULTS
Moderate differences (up to ~20%) in the numbers of cells that were separated from the individual blood samples were noted 24 hours after the first administration of fingolimod. After 3 months of therapy, however, the mean cell counts of sorted CD4-, CD8-, and CD19-expressing cells were significantly reduced by ~60%-90% compared to baseline (Table 1 ). The numbers of circulating CD14+ and CD56+ cells showed strong interindividual differences but, on average, remained relatively stable even after continued drug administration ( Figure 1A ).
The transcriptome analysis of the 5 immune cell populations revealed only a single DEG 24 hours after treatment initiation (Table 1) .
At this time point, solely the signal intensities of the probe set "TC10001500.hg.1" (no official gene symbol available) were significantly increased in the CD4+ cell subset. The lack of early gene regulatory effects reflects that the first dose of fingolimod does not have a lasting effect on the frequencies of blood cell populations and also
indicates that S1P receptor downstream signaling does not elicit a discernible transcriptional response in these cells.
Significant alterations in the transcriptome profiles were seen after 3 months of fingolimod therapy ( Table 1 Shown are the effects of fingolimod therapy on average absolute counts of cells sorted from the peripheral blood of relapsing-remitting MS patients (see also Figure 1A ). In comparison with baseline, significant changes in the number of circulating cells were only observed after 3 mo of treatment for CD4+ cells (Student's t test P-value = 0.00002), CD8+ cells (P = 0.027), and CD19+ cells (P = 0.00006). Moreover, the number of differentially expressed genes (DEG, t test P-values <0.001 and fold changes >1.5 or <−1.5) is indicated for each cell population and each time point during therapy (see also Figure 1D ). There was basically no increase or decrease in expression 24 h after the first dose of fingolimod. In contrast, after 3 mo of treatment, huge transcriptome alterations were seen in CD4+ cells and CD8+ cells. For CD19+ B cells, there were 42 DEG despite a strong reduction in the respective cell count of almost 90%.
T A B L E 1 Overview of fingolimodinduced cellular and transcriptome shifts for different blood cell populations
The huge transcriptome shifts in CD4+ cells and CD8+ cells clearly display the selective homing of T cell subpopulations to lymphoid tissues in response to sustained fingolimod therapy. 12, 13 On the contrary, the gene expression changes in CD19+ B cells were quite subtle considering the fact that their cell count was also remarkably reduced in the peripheral blood by almost 90% after 3 months (Table 1) . As the purity of isolated B cells was high before and during therapy ( Figure S1 ), this indicates that fingolimod similarly affects the trafficking of the different B cell subpopulations. Overall, 41 genes
showed an up to 5-fold increase in expression, while just 1 transcript (probe set "TC15000493.hg.1") was expressed at lower levels in the CD19+ cell subset during therapy ( Figure 1C) . Five of these genes remained significant at the 5% FDR level ( Table 2) . Predictions of TFBS revealed 5 TF to be associated with the DEG at the significance level α = 0.05. This information was used as template for modeling the underlying GRN using TILAR. In total, 42 genes were filtered as differentially expressed with t test P-values <0.001 and fold changes (FC) >1.5 or <−1.5 in CD19+ B cells when comparing the data at baseline with the data at 3 mo of treatment. The table provides the Affymetrix microarray gene-level probe set identifiers, the chromosome positions of the genes (GRCh37/hg19 genome assembly) in sorted order, FC, raw t test P-values, the number of 25mer oligonucleotide probes for each probe set as well as official gene symbols if available. Symbols in brackets (n = 21) indicate that the respective probe set interrogates only a part of a protein-coding gene or a noncoding RNA class. We marked the genes that were also expressed at significantly higher transcript levels in CD4+ cells ("2 sets," n = 24) or in both CD4+ cells and CD8+ cells ("3 sets," n = 11) as depicted in Figure 1D . *Significant at false discovery rate of 5%. Additional gene regulatory effects independent of S1P receptor binding, however, could not be evidenced in these cells in our study. The transcriptome shift in T cells and its impact on biological processes and S1P-related pathways are presented in detail in our previous publications. 12, 13 In the following, we will focus on the results for the subset of B cells, which recently gained increasing attention in MS research.
23,24
Other studies have shown that the absolute numbers of naive B cells, memory B cells, and plasmablasts are significantly reduced in the peripheral blood during fingolimod treatment. [25] [26] [27] As all these subpopulations are affected, only 42 DEG passed our filtering criteria when comparing the gene expression levels in separated CD19+ cells antigen-receptor signaling in B cells and T cells. 36 The related family member PTPRJ also plays a role in lymphocyte signaling, particularly in B cell activation and B cell development. 36, 37 Notably, the filtered probe set for PTPRJ ("TC11002664.hg.1") matches only the 3′ untranslated region of the last exon, whereas the designated probe set for the full-length transcript ("TC11000412.hg.1") narrowly missed the significance threshold (t test P-value = 0.004).
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